Loading
Nanoparticle-based Drug Delivery / RNA Interference and Gene Delivery / Nanoplatforms for Cancer Theranostics · Journal article
Scientific Reports · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This in vitro proof-of-concept demonstrates that antibody-decorated ELART nanocarriers achieve rapid internalization (1–4 h) into CD20+, CD22+, or CD33+ hematopoietic tumor cells and that Cy5-labeled siRNA reduces mitochondrial membrane potential and cell viability in surrogate assays. The work is preliminary; it establishes feasibility of the platform but lacks comparator data, functional efficacy endpoints, and translation to in vivo or clinical evidence.
In vitro proof-of-concept study. CD20+, CD22+, or CD33+ hematopoietic cancer cells. Intervention: ELART nanocarriers decorated with CD20-, CD22-, or CD33-targeting antibodies, loaded with Cy3- or Cy5-labeled siRNA.
Nearly all target cells achieved internalization of Cy3- or Cy5-labeled siRNA within 1–4 h Exposure to Cy5-labeled non-functional siRNAs reduced mitochondrial membrane potential, detected by TMRM assay Cy5-labeled non-functional siRNAs reduced cell viability, detected by CellTiter-Glo assay
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work is not yet suitable for clinical translation. Researchers developing RNA-interference therapeutics may find the modular ELART platform of interest for future antibody-targeted delivery development, but efficacy, safety, and comparative data are required before clinical consideration.
Proof-of-concept study demonstrating nanocarrier delivery of cytotoxic agents to hematopoietic cancer cells in vitro; early-stage work without efficacy endpoints, clinical data, or comparative controls required to establish clinical relevance.
As stated by the source record.
Quoted from the source exactly as published.
This work is not yet suitable for clinical translation. Researchers developing RNA-interference therapeutics may find the modular ELART platform of interest for future antibody-targeted delivery development, but efficacy, safety, and comparative data are required before clinical consideration.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract The efficient and safe transfection of hematopoietic cells is a major hurdle that limits efficacy of therapeutic approaches like RNA-interference. We therefore used our modular EL ectrostatic A ntibody si R NA T argeted therapy platform (ELART) to develop nanocarriers decorated with antibodies for delivery of siRNA into hematopoietic CD20-, CD22-, or CD33-positive cells. To analyze internalization efficacy into tumor cells, we applied nanocarriers loaded with Cy3- or Cy5-labeled siRNA and reached nearly all target cells within 1–4 h. Exposure to Cy5-labeled non-functional siRNAs resulted in reduction of the mitochondrial membrane potential and reduced viability, as detected in tetramethylrhodamine methyl ester (TMRM) and CellTiter-Glo (CTG) assays. We concluded that with our modular nanocarrier system, we can transport cytotoxic agents such as cyanine dyes when bound to siRNA, as ELART nanocarriers safely complex anionic siRNA electrostatically and releases it intracellularly within the target cell. This proof-of-concept study shows that ELART nanocarriers can transport anti-cancer agents utilizing siRNA as carrier substance.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.